Precautions for Patients Taking Aromatase Inhibitors

Heery, Mary; Farley, Stephen; Sparkman, Rhett; Healy, John; Eighmy, William; Zahrah, George; Zelkowitz, Richard

doi:10.6004/jadpro.2020.11.2.6

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case, the growth of cancer cells will not depend on ER signals anymore. Diversion of this pathway also occurs in the use of aromatase inhibitor drugs which causes a decrease in their effectiveness (Heery et al 2020). Therefore, luminal breast cancer therapy still requires other specific targeted agents.…”

Section: Introductionmentioning

confidence: 99%

Hesperitin Synergistically Promotes the Senescence Induction of Pentagamavunone-1 in Luminal Breast Cancer Cells, T47D

Rifai,

Hanifa,

Zulfin

et al. 2024

J.Tropical Biodiversity Biotechnology

View full text Add to dashboard Cite

Pentagamavunone-1 (PGV-1), a curcumin analog, is a promising anticancer candidate for several cancers that have been proven in vitro and in vivo. However, the efficacy of PGV-1 against breast cancer is subject to improvement to achieve a more suitable application. Here we propose hesperitin, a citrus flavonoid, to increase the anticancer potency of PGV-1 in luminal breast cancer cells. We use the T47D cell as the model to investigate the effect of co-administration of PGV-1 and hesperitin on cell cycle block, apoptosis modulation, and senescence phenomena. PGV-1 and hesperitin showed strong and weak cytotoxicity with an IC50 value of 2 µM and 100 µM, respectively. The co-treatment of PGV-1 and hesperitin resulted in strong synergistic effects with combination index (CI) value of ≤ 0.2. This combination caused apoptosis in correlation with cell cycle disruption in G2/M phase at 48 h. In particular, PGV-1 and hesperitin combination increased the incidence of cellular senescence significantly higher than the single treatment. Despite its senescence potentiation, hesperitin did not induce senescence in normal cells. Taken together, hesperitin may increase the anticancer potency of PGV-1 by modulating cell cycle arrest and apoptosis via the senescence mechanism.

show abstract

Section: Introductionmentioning

confidence: 99%

Hesperitin Synergistically Promotes the Senescence Induction of Pentagamavunone-1 in Luminal Breast Cancer Cells, T47D

Rifai,

Hanifa,

Zulfin

et al. 2024

J.Tropical Biodiversity Biotechnology

View full text Add to dashboard Cite

show abstract

“…In 2018 and 2020, two articles on precautions for patients taking tamoxifen and precautions for patients taking aromatase inhibitors were published in the Journal of the Advanced Practitioner in Oncology ( Heery et al, 2018 , 2020 ). Since then, more information on drug interactions has come to light.…”

mentioning

confidence: 99%

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors

Heery, APRN, AOCNS, CBCN

2023

JADPRO

View full text Add to dashboard Cite

Tamoxifen and aromatase inhibitors are widely prescribed therapies for the treatment of breast cancer. Tamoxifen is a selective estrogen receptor modulator that treats hormone-sensitive breast cancers. Research has demonstrated that tamoxifen therapy improves survival and reduces the risk of developing recurrent invasive breast cancer by up to 40%. Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Research on aromatase inhibitors has demonstrated improved survival in postmenopausal women, postmenopausal women with metastasis, and premenopausal women under the age of 35 with ovarian ablation. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence and improve the effectiveness of these medications. Advanced practitioners are in a position to prescribe these therapies, review medication interactions, educate patients, impact patients’ quality of life, improve patients’ sense of control, and increase patients’ partnerships with their oncology providers.

show abstract

Breast cancer status, grading system, etiology, and challenges in Asia: an updated review

et al. 2023

View full text Add to dashboard Cite

The number of breast cancer incidences reported worldwide has increased tremendously over the years. Scoping down to Asia, in 2020, the reported incidences of breast cancer are appalling, comprising 1,026,171 cases, occupying up to 45.4% of cases across the globe. Breast cancer is a non-communicable disease, that emerges in variegated forms, self-subsistent, and the etiology is observed to be multifactorial, dependent on the individual reproductive pattern, hormonal factors, diet, physical activity, lifestyle, and exposure to certain advent procedures. Given this complexity, breast cancer is expected to undergo a persistent increment in the number of incidences in near future, exacerbating the public health quality, regardless of race, ethnicity, geographical subgroups, and socioeconomic. In this review article, the authors examine breast cancer in multiple facets, comprising the updated statistics on breast cancer, typically in Asia; etiology of breast cancer; diagnosis of breast cancer; grading system; and challenges in breast cancer from the country’s income perspective. Realizing the ever-increasing demand for quality treatment, here, the article also contemplates common therapies in breast cancer, such as breast-conserving therapy, mastectomy, postmastectomy radiation therapy, neoadjuvant chemotherapy, axillary surgery, chemotherapy, adjuvant medical therapies, biological and targeted therapies, and endocrine therapy. This review article intended to provide a brief yet broad panoramic view of breast cancer, to readers, ranging from newcomers, existing researchers, and relevant stakeholders in the topic of interest.

show abstract

Precautions for Patients Taking Aromatase Inhibitors

Cited by 3 publications

References 27 publications

Hesperitin Synergistically Promotes the Senescence Induction of Pentagamavunone-1 in Luminal Breast Cancer Cells, T47D

Hesperitin Synergistically Promotes the Senescence Induction of Pentagamavunone-1 in Luminal Breast Cancer Cells, T47D

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors

Breast cancer status, grading system, etiology, and challenges in Asia: an updated review

Contact Info

Product

Resources

About